A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy
Top Cited Papers
- 12 November 2015
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (4), 1103-1110.e11
- https://doi.org/10.1016/j.jaci.2015.10.005
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergyJournal of Allergy and Clinical Immunology, 2014
- The safety and efficacy of sublingual and oral immunotherapy for milk allergyJournal of Allergy and Clinical Immunology, 2011
- A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergyJournal of Allergy and Clinical Immunology, 2011
- Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel ReportJournal of Allergy and Clinical Immunology, 2010
- Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthmaJournal of Allergy and Clinical Immunology, 2010
- A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergyJournal of Allergy and Clinical Immunology, 2008
- Specific oral tolerance induction in children with very severe cow's milk–induced reactionsJournal of Allergy and Clinical Immunology, 2008
- IgE-Facilitated Antigen Presentation: Role in Allergy and the Influence of Allergen ImmunotherapyImmunology and Allergy Clinics of North America, 2006
- Omalizumab treatment downregulates dendritic cell FcεRI expressionJournal of Allergy and Clinical Immunology, 2003
- Humanized Anti-IgE mAb Hu-901 Prevents the Activation of Allergen-Specific T CellsInternational Archives of Allergy and Immunology, 2001